SPOTLIGHT: Late-stage cancer patients are over-tested

Doing screening tests on patients whose life expectancy is extremely limited because of cancer is not cost-effective, according to a new study published in the Journal of the American Medical Association. The study examined the issue of overtesting in late-stage cancer and raises new questions about overdiagnosis and overtreatment in the healthcare system. Too many tests can raise anxiety in patients and lead to unneeded follow-up tests and treatments that can have serious complications, the study found. Article

Suggested Articles

An influential group of Republican lawmakers released its latest healthcare plan, which closely resembles prior Affordable Care Act repeal efforts.

An ACA public option could lead to lower premiums for commercial plans by sparking more competition, an analysis found.

Centene Corporation posted $95 million in profit for the third quarter of 2019, which skyrocketed from $19 million in the third quarter of 2018.